Scholar Rock Holding Corporation (SRRK): Price and Financial Metrics


Scholar Rock Holding Corporation (SRRK): $51.33

-2.02 (-3.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SRRK to Watchlist
Sign Up

Industry: Biotech


Ranked

of 485

in industry

SRRK Stock Summary

  • With a price/sales ratio of 91.84, Scholar Rock Holding Corp has a higher such ratio than 96.23% of stocks in our set.
  • With a year-over-year growth in debt of 491.12%, Scholar Rock Holding Corp's debt growth rate surpasses 96.8% of about US stocks.
  • In terms of volatility of its share price, SRRK is more volatile than 93.97% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Scholar Rock Holding Corp are CMRX, ALPN, GLYC, SGMO, and EDIT.
  • SRRK's SEC filings can be seen here. And to visit Scholar Rock Holding Corp's official web site, go to scholarrock.com.

SRRK Stock Price Chart Interactive Chart >

Price chart for SRRK

SRRK Price/Volume Stats

Current price $51.33 52-week high $66.72
Prev. close $53.35 52-week low $9.53
Day low $50.00 Volume 151,083
Day high $54.00 Avg. volume 210,717
50-day MA $53.51 Dividend yield N/A
200-day MA $30.33 Market Cap 1.73B

Scholar Rock Holding Corporation (SRRK) Company Bio


Scholar Rock Holding Corporation discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was founded in 2012 and is based in Cambridge, Massachusetts.


SRRK Latest News Stream


Event/Time News Detail
Loading, please wait...

SRRK Latest Social Stream


Loading social stream, please wait...

View Full SRRK Social Stream

Latest SRRK News From Around the Web

Below are the latest news stories about Scholar Rock Holding Corp that investors may wish to consider to help them evaluate SRRK as an investment opportunity.

Scholar Rock Announces Senior Management Promotions

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that its Board of Directors has approved several promotions within the senior management team, including Gregory Carven, Ph.D. to Chief Scientific Officer, Junlin Ho, J.D. to General Counsel and Corporate Secretary, and George Nomikos, M.D., Ph.D. to Senior Vice President,

Business Wire | February 4, 2021

Scholar Rock Presents Preclinical Data for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a presentation at the 2021 TGFβ for Immuno-Oncology Drug Development Summit.

Yahoo | January 27, 2021

Scholar Rock Provides Corporate Update and Highlights Priorities for 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided a corporate update and highlighted priorities for 2021. “2020 was a transformative year for Scholar Rock with significant progress made both clinically and operationally with positive interim data from the TOPAZ trial providing initial proof-of-concept of apitegromab’s poten

Business Wire | January 11, 2021

Earnings Update: Scholar Rock Holding Corporation (NASDAQ:SRRK) Just Reported And Analysts Are Boosting Their Estimates

Scholar Rock Holding Corporation (NASDAQ:SRRK) just released its latest quarterly report and things are not looking...

Yahoo | November 13, 2020

Scholar Rock to Present at Upcoming Healthcare Conferences

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming virtual investor conferences:

Yahoo | November 12, 2020

Read More 'SRRK' Stories Here

SRRK Price Returns

1-mo -12.90%
3-mo 18.44%
6-mo 255.22%
1-year 250.61%
3-year N/A
5-year N/A
YTD 5.77%
2020 268.21%
2019 -42.62%
2018 N/A
2017 N/A
2016 N/A

Continue Researching SRRK

Here are a few links from around the web to help you further your research on Scholar Rock Holding Corp's stock as an investment opportunity:

Scholar Rock Holding Corp (SRRK) Stock Price | Nasdaq
Scholar Rock Holding Corp (SRRK) Stock Quote, History and News - Yahoo Finance
Scholar Rock Holding Corp (SRRK) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8542 seconds.